Bodihekang

Bodihekang is a clinical-stage biotechnology company headquartered in Beijing, China, focused on the development of next-generation cell therapies for oncology. The company specializes in engineering CAR-T and TCR-T cells specifically designed to target and eliminate solid tumors, which remain a significant challenge for conventional immunotherapies. Its lead program, BDHK-001, is a CAR-T cell therapy targeting Claudin 18.2, currently undergoing clinical evaluation for patients with advanced gastric and pancreatic cancers. Bodihekang utilizes a proprietary technology platform to enhance the persistence and efficacy of T cells within the tumor microenvironment. The company is committed to advancing its pipeline of cell-based medicines to address high unmet medical needs in the field of cancer treatment.